Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2021-10-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对公司全资子公司向参股公司提供财务资助暨关联交易事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 普洛药业股份有限公司 regarding a financial assistance and related party transaction involving a wholly-owned subsidiary and an associate company. It references regulatory guidelines for independent directors and confirms the legality and approval process of the transaction. The document is a formal board/management related announcement about a specific transaction and the independent directors' opinion on it. It is not a full financial report, audit report, or earnings release, nor is it a voting result or capital change announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management opinion and board approval of a transaction.
2021-10-21 Chinese
关于全资子公司向参股公司提供财务资助暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a financial assistance transaction between a company's wholly-owned subsidiaries and an associated company, which constitutes a related party transaction. It includes details about the transaction, the parties involved, financial figures, risk analysis, and board opinions. The document is titled as an "announcement" and is relatively short (2831 characters). It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is a regulatory announcement about a related party transaction, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Board/Management Information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-10-21 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '普洛药业股份有限公司 2021 年第三季度报告' which translates to 'Pu Luo Pharmaceutical Co., Ltd. 2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial metrics for the third quarter of 2021. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-21 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution from the company's board of directors meeting, specifically the eighth board's ninth meeting. It includes approval of the 2021 third quarter report and a related party transaction. The document is a board meeting resolution, not the actual quarterly report itself. It also mentions voting results on proposals. This fits the category of Board/Management Information (MANG) because it announces board decisions and approvals rather than providing the full financial report or detailed financial data. The document length is short and it is a meeting resolution, not a full report or announcement of report publication.
2021-10-21 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, market data, and potential impact on the company. The document is short (1234 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a drug approval and its implications for the company.
2021-10-12 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving a drug registration certificate from the national drug regulatory authority. It details the drug's specifications, approval, and potential impact on the company. The document is short (1104 characters) and serves as an official announcement rather than a financial report or detailed regulatory filing. It does not contain financial statements, management discussion, or detailed governance information. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about a significant company event related to product approval.
2021-09-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.